Previous Close | 9.20 |
Open | 9.20 |
Bid | 8.50 |
Ask | 9.10 |
Strike | 20.00 |
Expire Date | 2024-10-18 |
Day's Range | 9.20 - 9.20 |
Contract Range | N/A |
Volume | |
Open Interest | 94 |
A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that Pfizer's two-drug oral treatment would ease symptoms of long COVID after anecdotal reports of patients who said Paxlovid helped them.
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Pfizer stock is struggling to retake its 200-day line despite promising updates in cancer treatment. Is PFE stock now a sell?